November 23, 2016 - By Adrian Mccoy
The insider, and Momenta Pharmaceuticals Inc’s SVP – CFO, Richard Shea, unloaded 971 company shares on 23/11/2016, valued by the stock market at $13,276 (at $13.7 per share). Richard Shea now has rights to 131,156 shares of the Company. The mentioned shares were sold on 23/11/2016 and the Form 4 that contains the original information, filed with the U.S. SEC can be accessed here.
Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 26.27% above today’s ($13.55) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was downgraded by Goldman Sachs to “Neutral” on Thursday, August 6. Barclays Capital upgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Tuesday, October 11. Barclays Capital has “Overweight” rating and $19 price target. The firm has “Hold” rating by Maxim Group given on Friday, January 8. The company was initiated on Monday, June 6 by Goldman Sachs. The rating was initiated by JP Morgan on Friday, November 13 with “Overweight”. Leerink Swann maintained it with “Outperform” rating and $18 target price in Wednesday, May 4 report. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Hold” rating by Aegis Capital on Tuesday, November 22. As per Wednesday, September 7, the company rating was downgraded by Maxim Group. The firm has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. Barclays Capital initiated it with “Equal-Weight” rating and $22 target price in Monday, November 23 report.
Insitutional Activity: The institutional sentiment decreased to 1.35 in 2016 Q2. Its down 0.03, from 1.38 in 2016Q1. The ratio dived, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Amica Pension Fund Board Of Trustees has 72,382 shares for 0.1% of their US portfolio. Tiaa Cref Investment Limited Co last reported 210,108 shares in the company. Proshare Advsrs Lc has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Employees Retirement Association Of Colorado accumulated 15,811 shares or 0% of the stock. Amica Retiree Med last reported 11,264 shares in the company. Rhumbline Advisers holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 94,672 shares. Royal Retail Bank Of Canada last reported 25,579 shares in the company. Tocqueville Asset Management Limited Partnership holds 273,055 shares or 0.04% of its portfolio. Moreover, Qs Investors Ltd Liability has 0.03% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 277,058 shares. Laurion Cap Mgmt Limited Partnership last reported 0% of its portfolio in the stock. Swiss National Bank has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 1,677 shares. Goldman Sachs Group Incorporated accumulated 89,488 shares or 0% of the stock. Fiera holds 0.15% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 2.41M shares. Schwab Charles Inv Mngmt Inc holds 270,121 shares or 0% of its portfolio.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 6 insider sales for $188,231 net activity. Shares for $70,704 were sold by WHEELER CRAIG A. Roach James M. also sold $13,151 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares. 1,030 shares with value of $12,415 were sold by Leicher Bruce on Friday, August 19. Shea Richard P had sold 972 shares worth $11,717. Shapiro Bennett M sold $67,600 worth of stock or 5,200 shares. Shares for $12,644 were sold by Kaundinya Ganesh Venkataraman.
It is down 37.98% since April 21, 2016 and is uptrending. It has outperformed by 32.65% the S&P500.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $897.74 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It currently has negative earnings. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 earnings per share, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual earnings per share reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy